MBX Biosciences shares Phase 2 hypoparathyroidism data as it seeks to compete with Ascendis, AstraZeneca

MBX Biosciences said Monday that its experimental drug canvuparatide cleared the bar in a Phase 2 trial in a rare endocrine disorder called hypoparathyroidism. The once-weekly drug helped 63% of patients ...